Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
P04818

UPID:
TYSY_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
P04818; Q8WYK3; Q8WYK4

BACKGROUND:
Thymidylate synthase, a key enzyme in the folate metabolism pathway, facilitates the methylation of dUMP to dTMP, essential for DNA replication and repair. Its activity is critical for cell division and viability, highlighting its importance in both normal physiology and pathological conditions.

THERAPEUTIC SIGNIFICANCE:
Given its crucial role in DNA synthesis, thymidylate synthase's dysfunction is implicated in Dyskeratosis congenita, digenic. This association offers a promising avenue for therapeutic intervention, focusing on correcting the enzyme's activity to ameliorate disease symptoms and improve patient outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.